Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Lawrence Freedman, M.D.

Co-Author

This page shows the publications co-authored by Matthew Freedman and Sarah Abou Alaiwi.
Connection Strength

1.508
  1. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979.
    View in: PubMed
    Score: 0.239
  2. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 03 30; 34(13):108926.
    View in: PubMed
    Score: 0.239
  3. Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 Oct; 26(10):1663.
    View in: PubMed
    Score: 0.231
  4. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020 08; 52(8):790-799.
    View in: PubMed
    Score: 0.228
  5. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 07; 26(7):1041-1043.
    View in: PubMed
    Score: 0.226
  6. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
    View in: PubMed
    Score: 0.224
  7. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021 10 01; 12(1):5775.
    View in: PubMed
    Score: 0.062
  8. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
    View in: PubMed
    Score: 0.059
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.